Abstract highlights initial data from Phase 1 part of Phase 1/2 clinical trial of RP1 alone and in combination with Opdivo® (nivolumab)   WOBURN, Mass. , Oct. 02, 2019 (GLOBE NEWSWIRE) — Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived